MYND Life Sciences Signs Collaborative Research Agreement with UBC to Study Major Depression Feb 6, 2021
MINDCURE Helping Canadians Pursue “Mental Wealth” with Psychedelic Supplements and Digital Therapeutics Feb 5, 2021
Curious About Ketamine? Field Trip Health Webinar Provides Insight Into the “Next Frontier” of Psychedelic Medicine Feb 5, 2021
MYND Life Sciences CEO Dr. Lyle Oberg Provides Research Updates, Plans for Public Listing Feb 2, 2021
Champignon Brands’ Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment Feb 1, 2021
